Quantitative structure-activity relationships of insecticidal pyrazolines
摘要:
AbstractMethyl 3‐(4‐chlorophenyl)‐4‐methyl‐1‐[N‐(4‐substituted pheny1)carba‐moy1]‐2‐pyrazoline‐4‐carboxylates and related compounds were prepared. Their convulsant activity was determined as the minimum dose required to bring about the symptom within 1 h after injection against male adult American cockroaches, Periplaneta americana (L.). Insecticidal activity with metabolic inhibitors for oxidation and hydrolysis was measured 24 h after injection of the test compounds. Variations in each of the activities were analysed by using physicochemical substituent parameters and regression analysis. The findings indicated that the greater the hydrophobicity and the more the electron‐withdrawing property of the substituents, the higher were the activities. Variations in each of the two activities were parabolically related to the STERIMOL width parameter with an optimum value of about zero.
[EN] INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS<br/>[FR] INHIBITION DE RAF KINASE AU MOYEN D'UREES HETEROCYCLIQUES SUBSTITUEES
申请人:BAYER CORPORATION
公开号:WO1999032106A1
公开(公告)日:1999-07-01
(EN) Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.(FR) L'invention a trait à des méthodes de traitement de tumeurs induites par la raf kinase, au moyen de composés d'urées substituées, et à ces composés en soi.
用替代尿素化合物治疗由raf激酶介导的肿瘤的方法,以及这些化合物本身。
[EN] INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS<br/>[FR] INHIBITION DE L'ACTIVITE DE P38 KINASE AU MOYEN D'UREES HETEROCYCLIQUES SUBSTITUEES
申请人:BAYER CORPORATION
公开号:WO1999032111A1
公开(公告)日:1999-07-01
(EN) This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.(FR) L'invention a trait à l'utilisation d'un groupe d'aryle urées pour traiter des maladies, autres que le cancer, induites par des cytokines, et des maladies, autres que le cancer, induites par des enzymes protéolytiques; et à des compositions utiles pour ce type de thérapie.